UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT
OF 1934
For the month of June 2020
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
o
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes o No x
If “Yes” is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
| |
Medicure
Inc. |
| |
(Registrant) |
| |
|
| |
|
|
| Date: June 25, 2020 |
By: |
/s/ Dr. Albert D.
Friesen |
| |
Dr. Albert D. Friesen |
| |
Title: CEO |
Exhibit
99.1
Medicure Announces a Direct to Patient Online Pharmacy Program for
Distribution of ZYPITAMAG™ (Pitavastatin) Tablets
WINNIPEG, MB, June 25, 2020 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV:MPH),
(OTC:MCUJF), a pharmaceutical company, is pleased to announce the
launch of a direct to patient online pharmacy program for the
distribution of ZYPITAMAGTM in the United States.
This program offers many advantages to Medicure to facilitate an
increase in patient access to ZYPITAMAGTM for patients
who hold a prescription, which includes direct shipment of the
product to a patient's home at no cost, the processing of prior
authorizations, and direct to patient refill reminders. Ultimately,
marketing and distribution of ZYPITAMAGTM through this
program will provide reduced costs to the patient, including no
retail pharmacy filling fees, and increase the availability of the
product to consumers. It also provides a seamless process for
physicians and prescribers, and reduces their workload by
processing any prior authorization.
"We are excited to kickoff this online program to increase patient
access to ZYPITAMAGTM across the United States and
reduce one of the impediments to the growth of the product"
commented Medicure's CEO, Dr. Albert D. Friesen. "We look
forward to growing the ZYPITAMAGTM brand as part of our
portfolio of cardiovascular products."
About Medicure Inc.
Medicure is a pharmaceutical company
focused on the development and commercialization of therapies for
the U.S. cardiovascular market. The present focus of the Company is
the marketing and distribution of
AGGRASTAT® (tirofiban hydrochloride) injection,
ZYPITAMAGTM (pitavastatin) tablets and the ReDS PRO™
device in the United States, where they are sold through the
Company's U.S. subsidiary, Medicure Pharma Inc. For more
information on Medicure please visit www.medicure.com. For
additional information about ZYPITAMAGTM, refer to the
full Prescribing Information.
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this
press release that are not statements of historical fact,
including, without limitation, statements containing the words
"believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are
hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, include estimates,
analysis and opinions of management of the Company made in light of
its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, expected
future growth in revenues, stage of development, additional capital
requirements, risks associated with the completion and timing of
clinical trials and obtaining regulatory approval to market the
Company's products, the ability to protect its intellectual
property, dependence upon collaborative partners, changes in
government regulation or regulatory approval processes, and rapid
technological change in the industry. Such statements are based on
a number of assumptions which may prove to be incorrect, including,
but not limited to, assumptions about: general business and
economic conditions; the impact of changes in Canadian-US dollar
and other foreign exchange rates on the Company's revenues, costs
and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; results of
current and future clinical trials; the uncertainties associated
with the acceptance and demand for new products and market
competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended December 31,
2019.
View original
content:http://www.prnewswire.com/news-releases/medicure-announces-a-direct-to-patient-online-pharmacy-program-for-distribution-of-zypitamag-pitavastatin-tablets-301083656.html
SOURCE Medicure Inc.
View original content:
http://www.newswire.ca/en/releases/archive/June2020/25/c2825.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial
Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail:
info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 08:30e 25-JUN-20
This regulatory filing also includes additional resources:
ex991.pdf
